Novartis

Two new studies are raising concerns that the CRISPR-Cas9 gene editing system could trigger an increased cancer risk in cells. With human trials using the technique starting this year, the scientists behind these new studies urge researchers to be aware of this cancer-driving mechanism.

Earlier this year, Google announced that it was testing a glucose-monitoring contact lens. The lens is aimed at helping people with diabetes better manage the disease. A partnership has now been announced with Alcon, which is the eye care division of Novartis, to commercialize the technology.